MCID: UTR011
MIFTS: 43

Uterine Corpus Serous Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Uterine Corpus Serous Adenocarcinoma

MalaCards integrated aliases for Uterine Corpus Serous Adenocarcinoma:

Name: Uterine Corpus Serous Adenocarcinoma 12 15
Uterine Papillary Serous Carcinoma 12
Endometrial Serous Adenocarcinoma 73
Uterine Serous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5750
NCIt 50 C27838
UMLS 73 C1336921

Summaries for Uterine Corpus Serous Adenocarcinoma

Disease Ontology : 12 A uterine corpus cancer that is characterized histologically by papillae with fibrovascular cores, marked nuclear atypia, psammoma bodies and cilia.

MalaCards based summary : Uterine Corpus Serous Adenocarcinoma, also known as uterine papillary serous carcinoma, is related to endometrial cancer and papillary serous adenocarcinoma. An important gene associated with Uterine Corpus Serous Adenocarcinoma is KIAA1324 (KIAA1324), and among its related pathways/superpathways are Chks in Checkpoint Regulation and Glioma. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include liver, endothelial and uterus, and related phenotypes are Decreased viability with cisplatin and Synthetic lethal with cisplatin

Related Diseases for Uterine Corpus Serous Adenocarcinoma

Diseases related to Uterine Corpus Serous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 95)
# Related Disease Score Top Affiliating Genes
1 endometrial cancer 28.1 BRCA1 BRCA2 ERBB2 TP53
2 papillary serous adenocarcinoma 10.3 BRCA1 TP53
3 myxosarcoma 10.3 BRCA1 TP53
4 gallbladder squamous cell carcinoma 10.2 ERBB2 TP53
5 gastric papillary adenocarcinoma 10.2 ERBB2 TP53
6 non-proliferative fibrocystic change of the breast 10.2 ERBB2 TP53
7 pleomorphic adenoma carcinoma 10.2 ERBB2 TP53
8 uterine body mixed cancer 10.2 ERBB2 TP53
9 glioma susceptibility 1 10.2 ERBB2 TP53
10 breast squamous cell carcinoma 10.2 ERBB2 TP53
11 oral leukoplakia 10.2 ERBB2 TP53
12 microglandular adenosis 10.2 ERBB2 TP53
13 nijmegen breakage syndrome 10.2 BRCA1 TP53
14 breast benign neoplasm 10.2 ERBB2 TP53
15 thoracic benign neoplasm 10.2 ERBB2 TP53
16 esophagus adenocarcinoma 10.2 ERBB2 TP53
17 mixed cell type cancer 10.2 ERBB2 TP53
18 ovary adenocarcinoma 10.2 ERBB2 TP53
19 breast medullary carcinoma 10.1 BRCA1 ERBB2
20 granulosa cell tumor of the ovary 10.1 ERBB2 TP53
21 hidradenocarcinoma 10.1 ERBB2 TP53
22 papillary adenocarcinoma 10.1 ERBB2 TP53
23 barrett's adenocarcinoma 10.1 ERBB2 TP53
24 sweat gland cancer 10.1 ERBB2 TP53
25 bladder squamous cell carcinoma 10.1 ERBB2 TP53
26 lobular neoplasia 10.1 BRCA1 ERBB2
27 serous cystadenocarcinoma 10.1 ERBB2 TP53
28 cervical adenocarcinoma 10.0 ERBB2 TP53
29 estrogen-receptor positive breast cancer 10.0 ERBB2 TP53
30 cystadenocarcinoma 10.0 ERBB2 TP53
31 endometrial adenocarcinoma 10.0 ERBB2 TP53
32 estrogen-receptor negative breast cancer 10.0 BRCA1 ERBB2
33 tetraploidy 10.0 BRCA2 TP53
34 ovarian serous cystadenocarcinoma 10.0 ERBB2 TP53
35 insulin-like growth factor i 10.0
36 adenocarcinoma 10.0
37 pleomorphic adenoma 9.9 ERBB2 TP53
38 uterine anomalies 9.9
39 pulmonary fibrosis 9.9
40 ovarian serous carcinoma 9.9
41 thrombocytosis 9.9
42 hereditary site-specific ovarian cancer syndrome 9.9 BRCA1 BRCA2
43 renal cell carcinoma, papillary, 1 9.9 ERBB2 TP53
44 breast reconstruction 9.9 BRCA1 BRCA2
45 nosophobia 9.9 BRCA1 BRCA2
46 cancerophobia 9.9 BRCA1 BRCA2
47 oral cavity cancer 9.9 ERBB2 TP53
48 breast-ovarian cancer, familial 1 9.9 BRCA1 BRCA2
49 acinar cell carcinoma 9.9 BRCA2 TP53
50 peritoneum cancer 9.9 BRCA1 BRCA2

Graphical network of the top 20 diseases related to Uterine Corpus Serous Adenocarcinoma:



Diseases related to Uterine Corpus Serous Adenocarcinoma

Symptoms & Phenotypes for Uterine Corpus Serous Adenocarcinoma

GenomeRNAi Phenotypes related to Uterine Corpus Serous Adenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with cisplatin GR00101-A-4 8.96 BRCA1 BRCA2
2 Synthetic lethal with cisplatin GR00101-A-1 8.62 BRCA1 BRCA2

MGI Mouse Phenotypes related to Uterine Corpus Serous Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.91 ERBB2 APRT KIAA1324 TP53 BRCA1 BRCA2
2 homeostasis/metabolism MP:0005376 9.85 BRCA2 ERBB2 KIAA1324 APRT TP53 BRCA1
3 integument MP:0010771 9.72 ERBB2 APRT TP53 BRCA1 BRCA2
4 digestive/alimentary MP:0005381 9.71 BRCA2 ERBB2 TP53 BRCA1
5 mortality/aging MP:0010768 9.63 BRCA2 ERBB2 KIAA1324 APRT TP53 BRCA1
6 limbs/digits/tail MP:0005371 9.56 BRCA2 ERBB2 TP53 BRCA1
7 neoplasm MP:0002006 9.26 ERBB2 TP53 BRCA1 BRCA2
8 reproductive system MP:0005389 9.1 ERBB2 APRT KIAA1324 TP53 BRCA1 BRCA2

Drugs & Therapeutics for Uterine Corpus Serous Adenocarcinoma

Drugs for Uterine Corpus Serous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Lenograstim Approved, Investigational Phase 3,Phase 1 135968-09-1
4
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
5
Doxorubicin Approved, Investigational Phase 3,Phase 1 23214-92-8 31703
6
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
7
Everolimus Approved Phase 2, Phase 3 159351-69-6 6442177
8
Sirolimus Approved, Investigational Phase 2, Phase 3 53123-88-9 5284616 6436030 46835353
9
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
10
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
11
Doxil Approved June 1999 Phase 3,Phase 1 31703
12 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
13 Antimitotic Agents Phase 3,Phase 2,Phase 1
14 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
15 Adjuvants, Immunologic Phase 3,Phase 1
16 Topoisomerase Inhibitors Phase 3,Phase 1
17 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
18 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
19 Immunosuppressive Agents Phase 2, Phase 3
20 Anti-Infective Agents Phase 2, Phase 3,Phase 1
21 Antifungal Agents Phase 2, Phase 3
22 Hypoglycemic Agents Phase 2, Phase 3
23 Steroid Synthesis Inhibitors Phase 2, Phase 3
24 Hormone Antagonists Phase 2, Phase 3
25 Hormones Phase 2, Phase 3
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
27 Estrogen Antagonists Phase 2, Phase 3
28 Estrogens Phase 2, Phase 3
29 Aromatase Inhibitors Phase 2, Phase 3
30
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
31
Ifosfamide Approved Phase 2 3778-73-2 3690
32
Mesna Approved, Investigational Phase 2 3375-50-6 598
33
Nintedanib Approved Phase 2 656247-17-5 56843413
34
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
35
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
36
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
37
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
38
Cediranib Investigational Phase 2 288383-20-0 9933475
39
Trebananib Investigational Phase 2 894356-79-7
40
Maleic acid Experimental Phase 2 110-16-7 444266
41 Imatinib Mesylate Phase 1, Phase 2 220127-57-1 123596
42
Isophosphamide mustard Phase 2 0
43 Alkylating Agents Phase 2
44 Mitogens Phase 2,Phase 1
45 Angiogenesis Inhibitors Phase 2,Phase 1
46 Angiogenesis Modulating Agents Phase 2,Phase 1
47 Endothelial Growth Factors Phase 2,Phase 1
48 Immunoglobulin Fc Fragments Phase 2
49 Immunoglobulin G Phase 2,Phase 1
50 Antibodies Phase 2,Phase 1

Interventional clinical trials:

(show all 40)
# Name Status NCT ID Phase Drugs
1 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
2 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
3 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
4 Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Active, not recruiting NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
5 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
6 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
7 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
8 Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer Unknown status NCT02112552 Phase 2 Paclitaxel;Carboplatin
9 Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Completed NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel
10 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
11 Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer Completed NCT00022620 Phase 2 paclitaxel
12 Uterine Papillary Serous Cancer (UPSC) Trial Completed NCT00147680 Phase 2 Paclitaxel, Carboplatin
13 A Phase II Trial of Adjuvant Radiation Therapy With Ifosfamide in Patients With MMT of the Uterus Completed NCT00231842 Phase 2 Ifosfamide
14 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
15 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01132820 Phase 2 Cediranib Maleate
16 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
17 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2 Nintedanib
18 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
19 Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
20 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT01210222 Phase 2
21 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00888173 Phase 2 Brivanib Alaninate
22 A Phase II Evaluation of Afatinibin Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma Recruiting NCT02491099 Phase 2 Afatinib
23 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
24 Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Recruiting NCT00492778 Phase 2 Cisplatin
25 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT00478426 Phase 2 Sunitinib Malate
26 Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Active, not recruiting NCT00977574 Phase 2 Carboplatin;Ixabepilone;Paclitaxel;Temsirolimus
27 Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer Suspended NCT02728258 Phase 2 Copanlisib
28 Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Suspended NCT01935934 Phase 2 Cabozantinib S-malate
29 A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers Terminated NCT00231829 Phase 2 Celecoxib
30 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00005840 Phase 1 Paclitaxel;Cisplatin
31 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00005830 Phase 1 Doxorubicin Hydrochloride;Cisplatin
32 Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Completed NCT01440998 Phase 1 Carboplatin;Dasatinib;Paclitaxel
33 Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer Completed NCT00575952 Phase 1 Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
34 Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer Recruiting NCT03325634 Phase 1
35 VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer Recruiting NCT03120624 Phase 1 Technetium Tc-99m Sodium Pertechnetate
36 TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Recruiting NCT02142803 Phase 1 Sapanisertib
37 Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Active, not recruiting NCT01935973 Phase 1 Trametinib;Uprosertib
38 Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Not yet recruiting NCT03552471 Phase 1 Rucaparib Camsylate
39 Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery Active, not recruiting NCT02315469
40 Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer Not yet recruiting NCT01344837

Search NIH Clinical Center for Uterine Corpus Serous Adenocarcinoma

Genetic Tests for Uterine Corpus Serous Adenocarcinoma

Anatomical Context for Uterine Corpus Serous Adenocarcinoma

MalaCards organs/tissues related to Uterine Corpus Serous Adenocarcinoma:

41
Liver, Endothelial, Uterus

Publications for Uterine Corpus Serous Adenocarcinoma

Articles related to Uterine Corpus Serous Adenocarcinoma:

(show all 20)
# Title Authors Year
1
HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas. ( 24698965 )
2014
2
Pulmonary fibrosis after pegylated liposomal Doxorubicin in a patient with uterine papillary serous carcinoma. ( 23358980 )
2013
3
Decreased expression of 14-3-3I8 is predictive of poor prognosis for patients with human uterine papillary serous carcinoma. ( 24201220 )
2013
4
Preoperative CA-125 predicts extra-uterine disease and survival in uterine papillary serous carcinoma patients. ( 22865295 )
2012
5
[Clinical significance of Her-2/neu status in patients with uterine papillary serous carcinoma]. ( 20646447 )
2010
6
Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma. ( 19476987 )
2009
7
Possible association between BRCA-1 carriers and incidence of uterine papillary serous carcinoma (UPSC). ( 17986237 )
2008
8
Establishment and characterization of a human cell line derived from a uterine papillary serous carcinoma with wild-type p53 function. ( 18667022 )
2008
9
The prognostic significance of thrombocytosis in uterine papillary serous carcinomas. ( 16934317 )
2007
10
A novel loss-of-function mutation in TP53 in an endometrial cancer cell line and uterine papillary serous carcinoma model. ( 17119852 )
2007
11
p53 and bcl-2 expression in invasive and pre-invasive uterine papillary serous carcinoma and atrophic endometrium. ( 16123814 )
2005
12
WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. ( 11939727 )
2002
13
No BRCA1 germline mutation in a family with uterine papillary serous carcinoma: a case report. ( 11766733 )
2001
14
p27 and cyclin D1 abnormalities in uterine papillary serous carcinoma. ( 10831356 )
2000
15
The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. ( 10419744 )
1999
16
Loss of p53 function in uterine papillary serous carcinoma. ( 9635683 )
1998
17
Uterine papillary serous carcinoma evolves via a p53-driven pathway. ( 8958301 )
1996
18
Immunocytochemical analysis of uterine papillary serous carcinomas for estrogen and progesterone receptors. ( 8005733 )
1994
19
Death rate and recurrence pattern among 841 clinical stage I endometrial cancer patients with special reference to uterine papillary serous carcinoma. ( 8112638 )
1993
20
Recurrence in noninvasive endometrial carcinoma. Relationship to uterine papillary serous carcinoma. ( 1928552 )
1991

Variations for Uterine Corpus Serous Adenocarcinoma

Copy number variations for Uterine Corpus Serous Adenocarcinoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 52344 11 16200000 21700000 Copy number SAA Uterine serous papillary cancer

Expression for Uterine Corpus Serous Adenocarcinoma

Search GEO for disease gene expression data for Uterine Corpus Serous Adenocarcinoma.

Pathways for Uterine Corpus Serous Adenocarcinoma

Pathways related to Uterine Corpus Serous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.36 BRCA1 BRCA2 TP53
2
Show member pathways
12.29 BRCA1 BRCA2 ERBB2 TP53
3
Show member pathways
12.22 BRCA1 BRCA2 ERBB2 TP53
4 12.16 BRCA1 ERBB2 TP53
5 12.14 BRCA1 BRCA2 TP53
6 11.73 BRCA1 BRCA2 TP53
7 11.45 ERBB2 TP53
8 11.38 ERBB2 TP53
9 11.34 BRCA1 ERBB2
10 11.26 BRCA1 TP53
11
Show member pathways
11.25 BRCA1 BRCA2 TP53
12 11.2 BRCA1 TP53
13 11.17 BRCA1 TP53
14 11 BRCA1 ERBB2 TP53
15 10.98 BRCA1 TP53
16 10.95 BRCA1 TP53
17 10.9 BRCA1 TP53
18 10.68 BRCA1 TP53
19 10.62 BRCA1 ERBB2 TP53

GO Terms for Uterine Corpus Serous Adenocarcinoma

Cellular components related to Uterine Corpus Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lateral element GO:0000800 8.62 BRCA1 BRCA2

Biological processes related to Uterine Corpus Serous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 9.72 BRCA1 BRCA2 TP53
2 positive regulation of gene expression GO:0010628 9.7 BRCA1 ERBB2 TP53
3 cell proliferation GO:0008283 9.69 BRCA2 ERBB2 TP53
4 double-strand break repair via homologous recombination GO:0000724 9.56 BRCA1 BRCA2
5 double-strand break repair GO:0006302 9.54 BRCA1 BRCA2
6 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.49 BRCA1 BRCA2
7 nucleotide-excision repair GO:0006289 9.48 BRCA2 TP53
8 DNA synthesis involved in DNA repair GO:0000731 9.46 BRCA1 BRCA2
9 response to gamma radiation GO:0010332 9.43 BRCA2 TP53
10 cell aging GO:0007569 9.4 BRCA2 TP53
11 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.37 BRCA2 TP53
12 positive regulation of cell cycle arrest GO:0071158 9.32 BRCA1 TP53
13 strand displacement GO:0000732 9.26 BRCA1 BRCA2
14 response to X-ray GO:0010165 9.16 BRCA2 TP53
15 chordate embryonic development GO:0043009 8.96 BRCA1 BRCA2
16 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.8 BRCA1 BRCA2 TP53

Molecular functions related to Uterine Corpus Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 8.96 ERBB2 TP53
2 damaged DNA binding GO:0003684 8.62 BRCA1 TP53

Sources for Uterine Corpus Serous Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....